Stephen Chandler, MD
Medical Oncology · Vancouver, WANPI 1043437098
Payments from drug & device makers
Across 44 payments — averaging $30.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$182
- Astellas Pharma US Inc$135
- Lilly USA, LLC$134
- Merck$122
- Exelixis Inc.$88
- Takeda Pharmaceuticals U.S.A., Inc.$78
- plus $611 from 19 others
What the payments were for
- Food & beverage$1,33999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $182 |
| Astellas Pharma US Inc | 2 | $135 |
| Lilly USA, LLC | 2 | $134 |
| Merck | 5 | $122 |
| Exelixis Inc. | 3 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $78 |
| Bayer | 2 | $62 |
| Seagen Inc. | 1 | $59 |
| Tersera Therapeutics LLC | 2 | $48 |
| Array Biopharma Inc | 2 | $46 |
| AbbVie(2 entities) | 2 | $45 |
| Genentech USA, Inc. | 2 | $34 |
| Sanofi | 1 | $32 |
| Gilead | 2 | $31 |
| Johnson & Johnson | 1 | $30 |
| Tempus AI, Inc | 1 | $29 |
| GSK | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Genmab U.S., Inc. | 1 | $22 |
| Incyte Corporation | 1 | $22 |
| Amgen | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$119
How this compares
$1,350 in reported general payments places this provider in the 20th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 17 | $4,741 |
| Anastrozole | 29 | $627 |
| Tamoxifen Citrate | 16 | $515 |
| Prochlorperazine Maleate | 16 | $359 |
| Oxycodone Hcl | 18 | $314 |
| Prednisone | 13 | $121 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Vancouver
- David CosgroveVancouver$1.5M
- Michael SchweizerSeattle$27.4M
- Ajay GopalSeattle$14.6M
- Scott TykodiSeattle$14.2M
- Evan YuSeattle$9.8M
- Christina BaikSeattle$9M
- David MaloneySeattle$8.5M
- Shailender BhatiaSeattle$7.5M
- Andrew CovelerSeattle$7.1M
- William BensingerLakewood$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.